All In Biotech

Drug Trial Radar · NCT07016802

A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD)

A Phase I, Randomized, Double-blind, Placebo and Active-controlled Study of Single and Multiple Ascending Doses of GenSci134 Injection in Healthy Adults, and a Single Ascending Dose in Patients With Adult Growth Hormone Deficiency

Last checked: Nov 20, 2026Latest source record: Apr 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

64

Planned (sponsor's estimate)

Start

Jun 9, 2025

Primary completion

Nov 25, 2026

Study completion Nov 25, 2026

Sponsor

Sponsor type
Industry
First posted
Jun 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To check how safe and well-tolerated a single subcutaneous injection of GenSc134 is in healthy male volunteers, a multiple-doses subcutaneous injection of GenSc134 is in healthy volunteers,a single subcutaneous injection of GenSc134 is in AGHD patients.

Conditions

  • Safety
  • Tolerability
  • Adult Growth Hormone Deficiency

Interventions

  • GenSci134Drug

    only one dose of GenSci134 to be given, subcutaneous , 7 dose level groups will be assigned.

  • PlaceboDrug

    only one dose of GenSci134 Placebo to be given, subcutaneous , 7 dose level groups will be assigned.

  • Recombinant Human Growth Hormone Injection (Norditropin®)Drug

    A single dose of 0.2 mg/day, administered once daily (QD) for 28 consecutive days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events and serious adverse eventsTime frame: From Day 0 to Month 3

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.